Trial reportActa obstetricia et gynecologica Scandinavica2026
Effects of vaginal microbiota transfer on social-emotional and neurodevelopment in cesarean-born infants: 12-month follow-up of a pilot randomized clinical trial.
Trial report in Acta obstetricia et gynecologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionTo evaluate the effects of vaginal microbiota transfer (VMT) on social-emotional development and to assess whether neurodevelopmental benefits observed at 6 months persist at 12 months in cesarean-born infants. MATERIAL AND
methodsThis 12-month follow-up study extended a prior randomized, placebo-controlled trial at a tertiary hospital in southern China. Cesarean-born infants were randomly assigned in a 1:1 ratio to receive maternal vaginal fluid (VMT group) or sterile saline-soaked gauze (Con group) immediately after delivery. Vaginally delivered mother-infant dyads served as a natural reference group (VD group). The primary endpoint of the original trial was infant neurodevelopment at 6 months. In this follow-up, social-emotion and neurodevelopment at 12 months were assessed using the Ages and Stages Questionnaires: Social-Emotional, Second Edition (ASQ:SE-2) and Third Edition (ASQ-3). Lower ASQ:SE-2 scores indicate better social-emotion skills, while higher ASQ-3 scores indicate better neurodevelopmental performance. This trial was registered with the Chinese Clinical Trial Registry, ChiCTR2000031326.
resultsA total of 210 mother-infant dyads were enrolled (VMT, Con, VD: n = 70 each) from December 10, 2020, to November 11, 2022. Infants in the VMT group had significantly lower ASQ:SE-2 total scores than those in the Con group (31.01% decrease; mean difference [MD]: -9.24; 95% confidence interval [95% CI]: -16.04 to -2.45), with improvements in self-regulation, social communication, and interaction with people. The VMT group also had higher ASQ-3 scores in the personal-social subdomain (MD: 4.65; 95% CI: 0.15 to 9.15), but no significant difference in total ASQ-3 scores (MD: 8.90; 95% CI, -2.9 to 20.70). No significant differences were found between the VMT and VD groups. The VMT group had a lower prevalence of social-emotional risk (adjusted RR: 0.39 [95% CI, 0.19 to 0.80]) than the Con group.
conclusionsThis pilot randomized clinical trial suggests that VMT may be associated with improved social-emotional development at 12 months in cesarean-born infants, although the neurodevelopmental benefits observed earlier appear to diminish over time. Given the small sample size and exploratory nature, the findings should be interpreted with caution. Larger, multi-center randomized controlled trials with longer follow-up are needed to confirm these results and further evaluate the VMT's effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.